DR. JAMES A CONOUR, MD
Psychiatric at 19 Ave, Portland, OR
License number
Oregon MD26028
Category
Psychiatric
Type
Psychiatry
Address
Address
847 NE 19Th Ave, Portland, OR 97232
Phone
(503) 228-7134
(503) 445-0749 (Fax)
(503) 294-1681
(503) 241-7419 (Fax)
(503) 445-0749 (Fax)
(503) 294-1681
(503) 241-7419 (Fax)
Personal information
See more information about JAMES A CONOUR at radaris.comName
Address
Phone
4212 SW Condor Ave, Portland, OR 97239
4212 Condor Ave, Portland, OR 97239
Professional information
Md At Cascadia Behavioral Healthcare
Position:
md at Cascadia Behavioral Healthcare
Location:
Portland, Oregon Area
Industry:
Health, Wellness and Fitness
Work:
Cascadia Behavioral Healthcare
-
md
James A Conour, Portland OR
Specialties:
Psychiatrist
Address:
232 Nw 6Th Ave, Portland, OR 97209
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)
Dr. James A Conour, Portland OR - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
Faulkner Place
13317 SE Powell Blvd, Portland 97236
(503) 760-9606 (Phone)
13317 SE Powell Blvd, Portland 97236
(503) 760-9606 (Phone)
Certifications:
Psychiatry, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Faulkner Place
13317 SE Powell Blvd, Portland 97236
Legacy Good Samaritan Medical Center
1015 West Ave #W121, Portland 97210
13317 SE Powell Blvd, Portland 97236
Legacy Good Samaritan Medical Center
1015 West Ave #W121, Portland 97210
Education:
Medical School
Southern Illinois University At Edwardsville
Graduated: 1999
Southern Illinois University At Edwardsville
Graduated: 1999
Compositions And Methods For The Treatment Of Catatonia
US Patent:
2014000, Jan 2, 2014
Filed:
Mar 20, 2012
Appl. No.:
14/005348
Inventors:
James Conour - Portland OR, US
International Classification:
A61K 31/53, A61K 31/405, A61K 31/554, A61K 31/5517, A61K 31/519, A61K 31/5513, A61K 31/5415
US Classification:
51421113, 514242, 514221, 5142258, 514220
Abstract:
Compositions and methods for treating psychotic and neurological disorders in a subject are disclosed. The compositions and methods utilize a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist. The compositions and methods are effective in reducing at least catatonic features in the subject.